Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
SHSE:600645'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.2 Med: 0.53 Max: 6.14
Current: 0.35
During the past 13 years, the highest Debt-to-EBITDA Ratio of Zhongyuan Union Cell & Gene Engineering was 6.14. The lowest was 0.20. And the median was 0.53.
SHSE:600645's Debt-to-EBITDA is ranked better than 73.11% of 305
companies
in the Biotechnology industry
Industry Median: 1.24
vs SHSE:600645: 0.35
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Zhongyuan Union Cell & Gene Engineering Debt-to-EBITDA Related Terms
Zhongyuan Union Cell & Gene Engineering Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhongyuan Union Cell & Gene Engineering Debt-to-EBITDA Chart
Zhongyuan Union Cell & Gene Engineering Annual Data
SHSE:600645 vs VRTX, REGN, MRNA: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Zhongyuan Union Cell & Gene Engineering's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhongyuan Union Cell & Gene Engineering Debt-to-EBITDA vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Zhongyuan Union Cell & Gene Engineering (SHSE:600645) has a Debt-to-EBITDA of 0.39 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Zhongyuan Union Cell & Gene Engineering. This is 26% below median its historical median of 0.53. Over the past decade, Zhongyuan Union Cell & Gene Engineering's Debt-to-EBITDA has ranged from 0.20 to 6.14. According to the industry distribution chart, Zhongyuan Union Cell & Gene Engineering ranks #82 out of 305 companies in the Biotechnology industry, placing it in the top 26.9%.
Is Zhongyuan Union Cell & Gene Engineering's Debt-to-EBITDA too high?
Zhongyuan Union Cell & Gene Engineering's current Debt-to-EBITDA of 0.39 is 26% below median its 10-year median of 0.53. Over the past 10 years, this metric has ranged from a low of 0.20 to a high of 6.14. The Biotechnology industry median Debt-to-EBITDA is 1.24. Zhongyuan Union Cell & Gene Engineering's value of 0.39 is 68.5% below this industry median. Based on the distribution chart, Zhongyuan Union Cell & Gene Engineering ranks #82 out of 305 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Zhongyuan Union Cell & Gene Engineering has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhongyuan Union Cell & Gene Engineering's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zhongyuan Union Cell & Gene Engineering ranks #82 out of 305 companies for Debt-to-EBITDA. This puts Zhongyuan Union Cell & Gene Engineering in the upper half of its industry. The industry median Debt-to-EBITDA is 1.24. Zhongyuan Union Cell & Gene Engineering's value of 0.39 is 68.5% below this benchmark. Historically, Zhongyuan Union Cell & Gene Engineering's own Debt-to-EBITDA has ranged from 0.20 to 6.14 over the past decade. While the company's 10-year median is 0.53 vs. the industry median of 1.24, Zhongyuan Union Cell & Gene Engineering has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.24, based on 305 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhongyuan Union Cell & Gene Engineering's current Debt-to-EBITDA of 0.39 is 68.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Zhongyuan Union Cell & Gene Engineering. For the Biotechnology industry, the median Debt-to-EBITDA is 1.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhongyuan Union Cell & Gene Engineering's current Debt-to-EBITDA is 0.39, which is 26% below median its own 10-year median of 0.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhongyuan Union Cell & Gene Engineering stock overvalued right now?
Based on GuruFocus' analysis, Zhongyuan Union Cell & Gene Engineering (SHSE:600645) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥20.74, compared to a current price of ¥18.62 — trading 10.2% below its estimated fair value. The current Debt-to-EBITDA is 0.39, which is 26% below median its 10-year median of 0.53 and 68.5% below the Biotechnology industry median of 1.24. Zhongyuan Union Cell & Gene Engineering's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Zhongyuan Union Cell & Gene Engineering (SHSE:600645), the current Debt-to-EBITDA is 0.39 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhongyuan Union Cell & Gene Engineering (SHSE:600645) Overvalued in 2026?
Based on GuruFocus' analysis, Zhongyuan Union Cell & Gene Engineering stock appears to be undervalued.
The current stock price of ¥18.62 is trading 10.2% below its estimated GF Value™ of ¥20.74.
GuruFocus considers Zhongyuan Union Cell & Gene Engineering to be Modestly Undervalued.
Key valuation signals for SHSE:600645:
Debt-to-EBITDA: 0.39 (26% below median its 10-year median of 0.53)
GF Value™: ¥20.74 vs. price of ¥18.62 (10.2% below fair value)
Industry Position: 68.5% below the Biotechnology median (#82 of 305)
No single metric tells the full story. See the SHSE:600645 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhongyuan Union Cell & Gene Engineering Corp Ltd is engaged in stem cell technology research, as well as detection and storage sources of stem cells in China. The company insists on the core strategy upon dual-core development of 'cell + gene' with the major businesses covering various cell storage businesses of newborns and adults; the preparation and storage of cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, adipose-derived stem cells and immune cells; genetic testing services relating to children's genes.
66GF Score
Get the complete analysis for SHSE:600645
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600645 has been successfully added to your 
